Coming May 2025
Get Early Access
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
138 employees
Neurelis: A specialty pharmaceutical company targeting unmet medical needs with unique solutions.
HQ
Founded
2007
Neurelis, founded with a mission to address unmet medical needs, is a specialty pharmaceutical company that focuses on developing innovative therapies for neurological conditions. The company's core vision is to enhance the quality of life for patients through unique and effective medical solutions. Neurelis offers products and services aimed at treating epilepsy and other central nervous system disorders, leveraging advanced technologies to create differentiated therapeutic options.
Notable individuals affiliated with Neurelis include Phil Haydon, PhD, who is also the President of Sail For Epilepsy, highlighting the company's commitment to community involvement. Neurelis has achieved significant milestones in its field, including the development of cutting-edge treatments that have positively impacted patients' lives. The company's focus on addressing critical gaps in neurological care has positioned it as a key player in the specialty pharmaceutical market, driving meaningful advancements in patient health and well-being.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Pharmaceuticals
Technology
Biotech
Tags
Healthtech
Model Types
Pharmaceutical
Revenue Type(s)
Recurring
Customer Type(s)
Consumers, Enterprise
Geographic Exposure
Global
When was Neurelis founded?
Neurelis was founded in 2007.
Where is Neurelis's headquarters located?
Neurelis's headquarters is located in San Diego, CA, US.
When was Neurelis's last funding round?
Neurelis's most recent funding round was for $114M (USD) in March 2021.
How many employees does Neurelis have?
Neurelis has 138 employees as of Feb 5, 2024.
How much has Neurelis raised to-date?
As of July 05, 2023, Neurelis has raised a total of $206.1M (USD) since Mar 10, 2021.
Add Comparison
Total Raised to Date
$206.1M
USD
Last Update Mar 10, 2021
Last Deal Details
$114M
USD
Mar 10, 2021
Series D
Current Employees
138
Last updated: Feb 5, 2024
No location information available for this company.
Locations
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts